The neural basis of psychedelic action

AC Kwan, DE Olson, KH Preller, BL Roth - Nature Neuroscience, 2022 - nature.com
Psychedelics are serotonin 2A receptor agonists that can lead to profound changes in
perception, cognition and mood. In this review, we focus on the basic neurobiology …

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

AK Schlag, J Aday, I Salam… - Journal of …, 2022 - journals.sagepub.com
Background: Despite an increasing body of research highlighting their efficacy to treat a
broad range of medical conditions, psychedelic drugs remain a controversial issue among …

[HTML][HTML] Single-dose psilocybin for a treatment-resistant episode of major depression

GM Goodwin, ST Aaronson, O Alvarez… - … England Journal of …, 2022 - Mass Medical Soc
Background Psilocybin is being studied for use in treatment-resistant depression. Methods
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …

Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized …

MP Bogenschutz, S Ross, S Bhatt, T Baron… - JAMA …, 2022 - jamanetwork.com
Importance Although classic psychedelic medications have shown promise in the treatment
of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To …

Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

AL Kaplan, DN Confair, K Kim, X Barros-Álvarez… - Nature, 2022 - nature.com
There is considerable interest in screening ultralarge chemical libraries for ligand discovery,
both empirically and computationally,,–. Efforts have focused on readily synthesizable …

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

N Gukasyan, AK Davis, FS Barrett… - Journal of …, 2022 - journals.sagepub.com
Background: Preliminary data suggest that psilocybin-assisted treatment produces
substantial and rapid antidepressant effects in patients with major depressive disorder …

[HTML][HTML] Trial of psilocybin versus escitalopram for depression

R Carhart-Harris, B Giribaldi, R Watts… - … England Journal of …, 2021 - Mass Medical Soc
Background Psilocybin may have antidepressant properties, but direct comparisons
between psilocybin and established treatments for depression are lacking. Methods In a …

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial

R von Rotz, EM Schindowski, J Jungwirth… - …, 2023 - thelancet.com
Background Psilocybin has been suggested as a novel, rapid-acting treatment for
depression. Two consecutive doses have been shown to markedly decrease symptom …

Structure-based discovery of nonhallucinogenic psychedelic analogs

D Cao, J Yu, H Wang, Z Luo, X Liu, L He, J Qi, L Fan… - Science, 2022 - science.org
Drugs that target the human serotonin 2A receptor (5-HT2AR) are used to treat
neuropsychiatric diseases; however, many have hallucinogenic effects, hampering their use …

[PDF][PDF] Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo

LX Shao, C Liao, I Gregg, PA Davoudian, NK Savalia… - Neuron, 2021 - cell.com
Psilocybin is a serotonergic psychedelic with untapped therapeutic potential. There are hints
that the use of psychedelics can produce neural adaptations, although the extent and …